



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

16 Nov 2020 (#50)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

- **[NOT-NS-21-006](#): Notice of Intent to Publish a Funding Opportunity Announcement for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)**. The purpose of this Notice is to inform potential applicants that the National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a re-issuance of funding opportunity announcement (FOA) [PAR-18-761](#). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
- **[NOT-NS-21-007](#): Notice of Intent to Publish a Funding Opportunity Announcement for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)**. The purpose of this Notice is to inform potential applicants that the National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a re-issuance of funding opportunity announcement (FOA) [PAR-18-762](#). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

Notices of Special Interest (NOSI)

- **[NOT-AI-21-002](#): Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects**. NIAID is issuing this Notice of Special Interest (NOSI) to highlight the critical need to develop prophylactic vaccines able to provide broad and durable protection against coronaviruses (CoVs), especially SARS-CoV-2 and others with pandemic potential. NIAID is particularly interested in highly collaborative, multi-disciplinary Program Projects (P01s) that incorporate understanding of CoV virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus (pan-CoV) vaccine candidates that provide broad protective immunity to multiple CoV strains. Applications in response to this NOSI must be submitted using the following funding opportunity: [PAR-20-072](#); NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)

Upcoming Deadlines

- **[Harnessing Data Science for Health Discovery and Innovation in Africa \(DS-I Africa\)](#)**:
Research Hubs non-AIDS application due date: 8 December 2020
Research Hubs AIDS application due date: 8 February 2021
- **[Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries D43](#)** 24 June 2021

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)

- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

1. Novel Approaches to Safe, Non-Invasive, Real Time Assessment of Human Placenta Development and Function Across Pregnancy (R01 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [PAR-18-884](#) **Type:** R01
Application Due Date: December 6, 2021. Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites grant applications that use novel approaches for the development of safe, real-time, non-invasive (or minimally invasive), in vivo methods to assess the development and function of the human placenta across pregnancy.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [PAR-21-070](#) **Type:** R61/R22
Application Due Date: March 17, 2021; March 17, 2022; March 17, 2023 Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative, interdisciplinary early-stage research to inform the development of innovative rapid, sensitive, simple, and cost-effective diagnostic technologies that will enable HIV self-testing during the earliest phases of acute infection or during viral rebound.
Budget:

3. National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [PAR-21-033](#) **Type:** R01
Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the [NCI DCTD website](#) and/or the [OHAM website](#) to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research; therefore, applications that propose phase III clinical trials will be deemed non-responsive and will not be reviewed.
Budget: Application budgets are limited to no more than \$499,999 in direct costs per year. The maximum project period is 5 years.

4. Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [PAR-21-035](#) **Type:** R01
Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA and the application instructions. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application

<p>Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University 5th Floor, Teaching Block, Tygerberg Campus. Enquiries: <i>Christa</i> e: cdevries@sun.ac.za t: +27 21 938 9838</p>	<p>Afdeling Navorsingsontwikkeling/Division for Research Development (DRD) Stellenbosch University 2038 Wilcocks Building, Ryneveld Street Enquiries: <i>Lizél</i> e: lizelk@sun.ac.za t: +27 21 808 2105</p>
--	---